LATE-BREAKING ABSTRACT: Attenuation of allergen-induced asthmatic responses by inhaled GATA-3 specific DNAzyme

N. Krug, J. Hohlfeld, A. M. Kirsten, O. Kornmann, K. Beeh, D. Kappeler, S. Korn, S. Ignatenko, C. Rogon, J. Bille, U. Homburg, A. Turowska, R. Buhl, J. Renz, H. Garn, H. Renz (Hannover, Großhansdorf, Frankfurt, Wiesbaden, Gauting, Mainz, Berlin, Munich, Marburg, Germany)

Source: International Congress 2014 – Latest insights in airway diseases
Session: Latest insights in airway diseases
Session type: Thematic Poster Session
Number: 2816
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Krug, J. Hohlfeld, A. M. Kirsten, O. Kornmann, K. Beeh, D. Kappeler, S. Korn, S. Ignatenko, C. Rogon, J. Bille, U. Homburg, A. Turowska, R. Buhl, J. Renz, H. Garn, H. Renz (Hannover, Großhansdorf, Frankfurt, Wiesbaden, Gauting, Mainz, Berlin, Munich, Marburg, Germany). LATE-BREAKING ABSTRACT: Attenuation of allergen-induced asthmatic responses by inhaled GATA-3 specific DNAzyme. Eur Respir J 2014; 44: Suppl. 58, 2816

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma.
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014

Species comparison of interleukin-13 induced airway hyperreactivity as model for allergic asthma
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014

LATE-BREAKING ABSTRACT: The CCR4 Antagonist CCX6239 for the treatment of allergic airways disease
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013

The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Blockade of TSLP pathway alters asthma biomarkers
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014

LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

Effectively targeting small airways using controlled inhalation for peripheral corticosteroid deposition
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014


Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014


LATE-BREAKING ABSTRACT: IL-5-induced airways eosinophilia as a negative regulator of TLR7 expression may impair the interferon response to rhinovirus in allergic airways
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014


LATE-BREAKING ABSTRACT: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting the allergen-induced early asthmatic response
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014


Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


LATE-BREAKING ABSTRACT: Inhibition of TRPA1 reduces airway inflammation and airway hyper-responsiveness in a murine model of allergic rhinitis
Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease
Year: 2016


Expression of CysLT2 receptors in asthmatic lung, and the roles in bronchoconstriction
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Adult asthma patients reporting exacerbations triggered by upper airway infection have increased total IgE and sensitization to HDM
Source: International Congress 2014 – New mechanisms in the pathogenesis of asthma and other lung diseases
Year: 2014


LATE-BREAKING ABSTRACT: Effect of inhaled kinase inhibitor on airway inflammation assessed in induced sputum after challenge with inhaled lipopolysaccharide
Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease
Year: 2016